Skip to main content
. 2022 May 28;22:364. doi: 10.1186/s12888-022-04008-9

Table 8.

Opinion of the scientific steering committee – addictive comorbidity

• In general, aripiprazole is a relevant choice for the treatment of patients with schizophrenia and an addictive comorbidity
• Aripiprazole should be considered as an appropriate choice for patients requiring a first-line antipsychotic treatment for a first psychotic episode who have a cannabis use disorder
• Aripiprazole should be considered as an appropriate therapeutic alternative for patients with an addictive comorbidity who are poorly controlled on their current antipsychotic
• In contrast, the presence of an addictive comorbidity is not a sufficient reason to switch a patient who is well-controlled on current medication to aripiprazole
• Management of patients with schizophrenia and an addictive comorbidity should involve both antipsychotic treatment, with for example aripiprazole, and therapies targeted specifically at reducing substance misuse